|

Ivosidenib Clinical Trials

13 actively recruiting trials across 5 locations

Also known as: AG-120, Ivosidenib Pill (daily 500 mg), S95031, TIBSOVO, Tibsovo

Pipeline

Phase 1: 3Phase 2: 6Phase 3: 1Phase 1/2: 2

Top Sponsors

  • M.D. Anderson Cancer Center4
  • Memorial Sloan Kettering Cancer Center2
  • University of Chicago1
  • UNICANCER1
  • Peking Union Medical College Hospital1

Indications

  • Cancer13
  • Acute Myeloid Leukemia5
  • Refractory Acute Myeloid Leukemia3
  • Recurrent Acute Myeloid Leukemia3
  • Myeloproliferative Neoplasm2

Other4 trials

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Phase 2
MRD-positive AML Clinical Study
N/A
Personalized Medicine for Advanced Biliary Cancer Patients
Phase 3
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
Phase 2

Houston, Texas3 trials

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 2
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

M D Anderson Cancer Center

Phase 1
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

M D Anderson Cancer Center

Phase 1/2

Boston, Massachusetts2 trials

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Dana-Farber Cancer Institute

Phase 1/2
Ivosidenib as Post-HSCT Maintenance for AML

Massachusetts General Hospital

Phase 2

Basking Ridge, New Jersey2 trials

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Memorial Sloan Kettering Basking Ridge

Phase 1
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Phase 2

Chicago, Illinois1 trial

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

University of Chicago Medicine Comprehensive Cancer Center

Phase 1

Columbus, Ohio1 trial

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

Ohio State University Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.